Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma


Dogan B. A. , Arduc A., Tuna M. M. , Berker D., Demirci N. , Demirtas S., ...Daha Fazla

ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, cilt.16, sa.1, ss.47-55, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Konu: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.2174/1871530316666160229120142
  • Dergi Adı: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS
  • Sayfa Sayıları: ss.47-55

Özet

Aim: Cabergoline is related to an elevated risk of fibrotic adverse reactions including cardiac valvular and pleuropulmonary fibrosis. We investigated pulmonary and cardiac valve fibrosis and immunological markers before and after 3 and 12 months of treatment with cabergoline in women with prolactinoma.